The U.S. Food and Drug Administration (FDA) has approved Revuforj (revumenib), which is a menin inhibitor, for the treatment ...

Biodesix expands its Bio-Rad partnership to validate ddPCR cancer assays, starting with ESR1 mutation testing in breast ...

Q3 2025 Earnings Call Transcript October 28, 2025 Incyte Corporation beats earnings expectations. Reported EPS is $2.11, ...

AI-advanced drug candidate achieves complete metabolic response after two cycles in patient who failed CAR-T and bispecific ...

Celcuity expects to complete a rolling NDA submission for gedatolisib under the FDA RTOR program by Q4 2025. Click here to ...

Mutations in ZRSR2 have been linked with disease progression in patients with JAK2 V617R – driven myeloproliferative ...

(Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced results from the Phase 3 ...

Get Apollo Global's Q3 earnings preview, segment outlook, and fair value insights. See if now is the right time to invest.

The latest update is out from Syndax Pharmaceuticals ( (SNDX) ).

Johnson & Johnson’s (J&J’s) bispecific Rybrevant (amivantamab) could provide an effective, novel option for patients with ...